Across TCGA pan-cancer cohorts, SCO1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SCO1 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher SCO1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SCO1 expression acts as an unfavorable survival marker.
THYM, LUSC, and ACC are the cancer types where SCO1 Mutation most reproducibly stratifies survival.